Scintigraphic Localization of Pheochromocytoma

James C. Sisson, Marc Frager, Timothy W. Valk, Milton D. Gross, Dennis P. Swanson, Donald M. Wieland, Michael C. Tobes, William H. Beierwaltes, Norman W. Thompson

New England Journal of Medicine · 1981 · 544 citations · 21 references

Concepts

TL;DR

The radiopharmaceutical [131I]MIBG accumulates in adrenergic vesicles, allowing retention in pheochromocytomas for days. We administered [131I]MIBG to eight patients and obtained scintigraphic images to localize pheochromocytomas. Scintigraphy with [131I]MIBG identified pheochromocytomas of varied size, location, and hormone secretion—including lesions missed by CT—and guided successful reoperation, demonstrating its safe and reliable localization capability.

Abstract

We used a new radiopharmaceutical agent, [131I]meta-iodobenzylguanidine ([131I]MIBG), to produce scintigraphic images of pheochromocytomas in eight patients. One day or more after injection, the only normal organ that displayed distinct concentrations of radioactivity was the urinary bladder. The [131I]MIBG was probably concentrated in adrenergic vesicles; in tissues where vesicles are numerous, such as pheochromocytomas, the radionuclide was retained for days. The spectrum of pheochromocytomas shown the scintigrams was broad: intra-adrenal and extraadrenal in location, benign and malignant in character, 0.2 to 65 g in weight, and with different hormone patterns in secretion. Tumors in four patients were not detected by computed tomography. In one patient, reoperation was undertaken only because the scintigram located the extra-adrenal tumors and thereby directed the surgeon's exploration. The method offers hope of safe and reliable localization of pheochromocytomas in their many guises.

References

21